Showing results (151-160 of 6,269) with videos related to

Sort By:
Pageof 627
Diabetes, Obesity & Metabolism|February 21, 2019
Effects of basal insulin glargine and omega-3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trialGilles R Dagenais, Hyejung Jung, Peter Bogaty, et al.
Diabetes, Obesity & Metabolism|February 21, 2019
Role of vagal activation in postprandial glucose metabolism after gastric bypass in individuals with and without hypoglycaemiaMarzieh Salehi, Amalia Gastaldelli, David A D'Alessio
Diabetes, Obesity & Metabolism|February 23, 2019
Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)Kirstine Brown-Frandsen, Scott S Emerson, Darren K McGuire, et al.
Diabetes, Obesity & Metabolism|November 21, 2018
Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis?Charlotte J Green, Thomas Marjot, Jeremy W Tomlinson, et al.
Diabetes, Obesity & Metabolism|February 16, 2019
Body mass index and insulin use as identifiers of high-cost patients with type 2 diabetes: A retrospective analysis of electronic health records linked to insurance claims dataStephen S Johnston, Eric M Ammann, Sangeetha R Kashyap, et al.
Diabetes, Obesity & Metabolism|February 16, 2019
The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world settingLuigi F Meneghini, Didac Mauricio, Emanuela Orsi, et al.
Diabetes, Obesity & Metabolism|March 8, 2019
Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?Rosalie A Scholtes, Michaël J B van Baar, Yuliya Lytvyn, et al.
Diabetes, Obesity & Metabolism|March 9, 2019
Longitudinal changes in glycated haemoglobin following treatment intensification after inadequate response to two oral antidiabetic agents in patients with type 2 diabetesKibum Kim, Sudhir Unni, Diana I Brixner, et al.
Diabetes, Obesity & Metabolism|February 19, 2021
Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 studyCarolyn S P Lam, Avraham Karasik, Cheli Melzer-Cohen, et al.
Diabetes, Obesity & Metabolism|February 19, 2021
Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trialRory J McCrimmon, Saud Al Sifri, Rifat Emral, et al.
Pageof 627